Antibacterial activity and clinical effect of balofloxacin in the urological field

T. Takenaka, R. Fujita, Toyohiko Watanabe, K. Monden, K. Sakuramoto, T. Hayashi, K. Hata, N. Ono, Y. Nasu, H. Kumon, H. Ohmori, Y. Katayama, M. Tsugawa

Research output: Contribution to journalArticle

Abstract

We studied the antimicrobacterial activity and clinical efficacy of balofloxacin (BLFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of BLFX were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). In general, the antibacterial activity of BLFX was inferior to that of OFLX, but almost equal to that of NFLX. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall efficacy rate was 80.0% (4/5) for chronic complicated UTI. Bacteriologically, eleven of the 12 strains isolated (91.7%) were eradicated. 3)Side effects: No clinical adverse reactions anti no abnormal laboratory findings were observed.

Original languageEnglish
Pages (from-to)324-329
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume43
Issue numberSUPPL. 5
Publication statusPublished - 1995

Fingerprint

Norfloxacin
Ofloxacin
Quinolones
Urinary Tract Infections
balofloxacin

Keywords

  • balofloxacin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Takenaka, T., Fujita, R., Watanabe, T., Monden, K., Sakuramoto, K., Hayashi, T., ... Tsugawa, M. (1995). Antibacterial activity and clinical effect of balofloxacin in the urological field. Japanese Journal of Chemotherapy, 43(SUPPL. 5), 324-329.

Antibacterial activity and clinical effect of balofloxacin in the urological field. / Takenaka, T.; Fujita, R.; Watanabe, Toyohiko; Monden, K.; Sakuramoto, K.; Hayashi, T.; Hata, K.; Ono, N.; Nasu, Y.; Kumon, H.; Ohmori, H.; Katayama, Y.; Tsugawa, M.

In: Japanese Journal of Chemotherapy, Vol. 43, No. SUPPL. 5, 1995, p. 324-329.

Research output: Contribution to journalArticle

Takenaka, T, Fujita, R, Watanabe, T, Monden, K, Sakuramoto, K, Hayashi, T, Hata, K, Ono, N, Nasu, Y, Kumon, H, Ohmori, H, Katayama, Y & Tsugawa, M 1995, 'Antibacterial activity and clinical effect of balofloxacin in the urological field', Japanese Journal of Chemotherapy, vol. 43, no. SUPPL. 5, pp. 324-329.
Takenaka T, Fujita R, Watanabe T, Monden K, Sakuramoto K, Hayashi T et al. Antibacterial activity and clinical effect of balofloxacin in the urological field. Japanese Journal of Chemotherapy. 1995;43(SUPPL. 5):324-329.
Takenaka, T. ; Fujita, R. ; Watanabe, Toyohiko ; Monden, K. ; Sakuramoto, K. ; Hayashi, T. ; Hata, K. ; Ono, N. ; Nasu, Y. ; Kumon, H. ; Ohmori, H. ; Katayama, Y. ; Tsugawa, M. / Antibacterial activity and clinical effect of balofloxacin in the urological field. In: Japanese Journal of Chemotherapy. 1995 ; Vol. 43, No. SUPPL. 5. pp. 324-329.
@article{4ffa012fadeb4c1dab4a3445f4a1d851,
title = "Antibacterial activity and clinical effect of balofloxacin in the urological field",
abstract = "We studied the antimicrobacterial activity and clinical efficacy of balofloxacin (BLFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of BLFX were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). In general, the antibacterial activity of BLFX was inferior to that of OFLX, but almost equal to that of NFLX. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall efficacy rate was 80.0{\%} (4/5) for chronic complicated UTI. Bacteriologically, eleven of the 12 strains isolated (91.7{\%}) were eradicated. 3)Side effects: No clinical adverse reactions anti no abnormal laboratory findings were observed.",
keywords = "balofloxacin",
author = "T. Takenaka and R. Fujita and Toyohiko Watanabe and K. Monden and K. Sakuramoto and T. Hayashi and K. Hata and N. Ono and Y. Nasu and H. Kumon and H. Ohmori and Y. Katayama and M. Tsugawa",
year = "1995",
language = "English",
volume = "43",
pages = "324--329",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Antibacterial activity and clinical effect of balofloxacin in the urological field

AU - Takenaka, T.

AU - Fujita, R.

AU - Watanabe, Toyohiko

AU - Monden, K.

AU - Sakuramoto, K.

AU - Hayashi, T.

AU - Hata, K.

AU - Ono, N.

AU - Nasu, Y.

AU - Kumon, H.

AU - Ohmori, H.

AU - Katayama, Y.

AU - Tsugawa, M.

PY - 1995

Y1 - 1995

N2 - We studied the antimicrobacterial activity and clinical efficacy of balofloxacin (BLFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of BLFX were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). In general, the antibacterial activity of BLFX was inferior to that of OFLX, but almost equal to that of NFLX. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall efficacy rate was 80.0% (4/5) for chronic complicated UTI. Bacteriologically, eleven of the 12 strains isolated (91.7%) were eradicated. 3)Side effects: No clinical adverse reactions anti no abnormal laboratory findings were observed.

AB - We studied the antimicrobacterial activity and clinical efficacy of balofloxacin (BLFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of BLFX were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). In general, the antibacterial activity of BLFX was inferior to that of OFLX, but almost equal to that of NFLX. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall efficacy rate was 80.0% (4/5) for chronic complicated UTI. Bacteriologically, eleven of the 12 strains isolated (91.7%) were eradicated. 3)Side effects: No clinical adverse reactions anti no abnormal laboratory findings were observed.

KW - balofloxacin

UR - http://www.scopus.com/inward/record.url?scp=0029559368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029559368&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029559368

VL - 43

SP - 324

EP - 329

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 5

ER -